Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN  
461.62
+12.24 (+2.72%)
4:28:00 PM EDT: $461.57 -0.05 (-0.01%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)50.79B
Current PE14.46
Forward PE 10.19
2yr Forward PE 11.37
See more stats
Estimates Current Quarter
Revenue$2.71 Billion
Adjusted EPS$10.33
See more estimates
10-Day MA$459.86
50-Day MA$490.76
200-Day MA$558.84
See more pivots

Regeneron Pharmaceuticals, Inc. Stock, NASDAQ:REGN

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
United States of America
Phone: +1.914.847.7000
Number of Employees: 9123

Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.